Login
HALOZYME THERAPEUTICS, INC. logo

HALOZYME THERAPEUTICS, INC.

halozyme.com

What Do They Do?

Licenses drug-delivery technology to biopharmaceutical companies and sells proprietary medicines and auto-injector products for pharmaceutical partners and healthcare providers.

How Do They Make Money?

Royalties are the largest stream: partners pay royalties as licensed products sell. Other revenue comes from product sales and collaboration fees, including upfront and milestone payments, bulk enzyme supplies and research services billed monthly.

revenue
SegmentShareRevenue
Royalties
Licensed

62%
FY2022: 55%
Product sales, net
Sold outright

27%
FY2022: 29%
Revenues under collaborative agreements
11%
FY2022: 16%

Who Are Their Customers?

Biopharmaceutical companies license technologies and buy bulk enzyme and development work; U.S. wholesale distributors buy Hylenex and XYOSTED and sell them to hospitals, surgery centers, pharmacies and government agencies.

Do Revenues Turn Into Profits?

Yes. It kept 23 cents of every revenue dollar as net income in FY2025 and turned 46 cents into free cash flow.

Operating income, FY2025
34% of revenue
▼ −15% vs FY2024 ($551.5M, 54%)
Net income, FY2025
23% of revenue
▼ −29% vs FY2024 ($444.1M, 44%)
Free cash flow, FY2025
46% of revenue
▲ +38% vs FY2024 ($468.4M, 46%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +39%
vs $354.3M in Q3 FY2025
Net income
▲ +41%
vs $175.2M in Q3 FY2025
Royalties share of revenue vs 66.6% in Q3 FY2025
  • Aug 6, 2026 Raised 2026 guidance and reported new technology collaborations The company raised its financial outlook and reported five new ENHANZE and Hypercon agreements through July.
  • Apr 30, 2026 Appointed Darren Snellgrove as chief financial officer He took over from Interim CFO David Ramsay, who moved to an advisory role.

Growing. Revenue grew 3.2x in 4 years, from $443.3M in FY2021 to $1.4B in FY2025, about 33% a year.

Broader delivery technology portfolio Halozyme's portfolio has expanded beyond ENHANZE and pressure-assisted injectors: the latest report adds Hypercon's microparticle and Surf Bio's polymer-based concentration technologies for injectable drugs.

High-volume auto-injectors High-volume auto-injectors move from development plans to part of the current platform lineup.

Revenue over time
Royalties Product sales, net Revenues under collaborative agreements
$2B$1B$0

Who Do They Compete With?

Competes with Alteogen, Amphastar Pharmaceuticals, AbbVie, Perrigo, Lilly, Endo, Pfizer, Tolmar Pharmaceuticals, Verity Pharmaceuticals, Marius Pharmaceuticals, Teva, Viatris, Scandinavian Health, Ypsomed, West Pharmaceutical, and Owen Mumford

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support